Lack of Association Between GSTM1 and GSTT1 Polymorphisms and Brain Tumour Risk

Sima, Xiutian; Zhong, Weiying; Liu, Jiangang; You, Chao

doi:10.7314/apjcp.2012.13.1.325

Cited by 7 publications

(4 citation statements)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include meta-analyses that suggest GSTM1 deficiency increases the risk of head and neck cancer (Hashibe et al, 2003;Ye et al, 2004;Tripathy and Roy, 2006), cervical cancers (Gao et al, 2011;Liu and Xu, 2012) and oral cancer ). However, a number of meta-analyses indicated no marked association of GSTM1 null mutations with hepatocellular cancer (White et al, 2008), brain tumours (Sima et al, 2012), colorectal cancers (Zhao et al, 2012), ovarian cancers (Economopoulos et al, 2010), melanoma (Nie et al, 2011). In this study, the results indicate that null GSTM1 genotype might increase susceptibility to NPC which was in accordance with the evidence-based meta-analysis pertaining to GSTM1 and GSTT1 polymorphisms on nasopharyngeal cancer by .…”

Section: Discussionsupporting

confidence: 88%

Meta-analysis of GSTM1 and GSTT1 Polymorphisms and Risk of Nasopharyngeal Cancer

Murthy¹,

Kumar²,

Suresh³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Studies of associations between genetic polymorphism of glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) with risk of nasopharyngeal cancer (NPC) have generated conflicting results. Thus, a meta-analysis was performed to clarify the effects of GSTM1 and GSTT1 polymorphisms on the risk of developing NPC. Materials and Methods: A literature search in two electronic databases namely PubMed and EMBASE up to December 2012 was conducted and eligible papers were finally selected based on the inclusion and exclusion criteria. The pooled odds ratio (OR) and presence of heterogeneity and publication bias in those studies were evaluated. Results: A total of 9 studies concerning nasopharyngeal cancer were evaluated. Analyses of all relevant studies showed increased NPC risk to be significantly associated with the null genotypes of GSTMI (OR=1.43, 95%CI 1.24-1.66) and GSTT1 (OR=1.28, 95%CI=1.09-1.51). In addition, evidence of publication bias was detected among the studies on GSTM1 polymorphism. Conclusions: This meta-analysis demonstrated the GSTM1 and GSTT1 null genotypes are associated with an increased risk of NPC.

show abstract

Section: Discussionsupporting

confidence: 88%

Meta-analysis of GSTM1 and GSTT1 Polymorphisms and Risk of Nasopharyngeal Cancer

Murthy¹,

Kumar²,

Suresh³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…However, no strong association between GSTM1 , GSTT1 , CASP8 , XRCC1 and meningioma susceptibility was obtained. The negative associations between GSTM1 and GSTT1 null/present and meningioma risk were partly in line with previous results on the role of GSTM1 and GSTT1 polymorphisms in brain-tumor risk 10,11. In spite of this, the possibility of potential roles of these polymorphisms in inherited meningioma risk still cannot be ruled out.…”

Section: Discussionsupporting

confidence: 87%

Genetic variants and increased risk of meningioma: an updated meta-analysis

Han

Wang

et al. 2017

OTT

View full text Add to dashboard Cite

PurposeVarious genetic variants have been reported to be linked to an increased risk of meningioma. However, no confirmed conclusion has been obtained. The purpose of the study was to investigate potential meningioma-associated gene polymorphisms, based on published evidence.Materials and methodsAn updated meta-analysis was performed in September 2016. After electronic database searching and study screening, we selected eligible case-control studies and extracted data for meta-analysis, using Mantel–Haenszel statistics. P-values, pooled odds ratios (ORs), and 95% confidence intervals were calculated.ResultsWe finally selected eight genes with ten polymorphisms: MLLT10 rs12770228, CASP8 rs1045485, XRCC1 rs1799782, rs25487, MTHFR rs1801133, rs1801131, MTRR rs1801394, MTR rs1805087, GSTM1 null/present, and GSTT1 null/present. Results of meta-analyses showed that there was increased meningioma risk in case groups under all models of MLLT10 rs12770228 (all OR >1, P<0.001), compared with control groups. Similar results were observed under the allele, homozygote, dominant, and recessive models of MTRR rs1801394 (all OR >1, P<0.05), and the heterozygote and dominant models of MTHFR rs1801131 in the Caucasian population (all OR >1, P<0.05). However, no significantly increased meningioma risks were observed for CASP8 rs1045485, XRCC1 rs25487, rs1799782, MTHFR rs1801133, MTR rs1805087, or GSTM1/GSTT1 null mutations.ConclusionOur updated meta-analysis provided statistical evidence for the role of MLLT10 rs12770228, MTRR rs1801394, and MTHFR rs1801131 in increased susceptibility to meningioma.

show abstract

“…Thus, our study provided more reliable association between the rs6010620 polymorphism in RTEL1 gene and risk of glioma which resulted in more reliable conclusion. In addition, previous studies have found the association between the gene polymorphisms and glioma risk, such as the Glutathione S-transferases (GSTs) gene polymorphism (Sima et al, 2012). It may contribute to the occurrence of glioma.…”

Section: Discussionmentioning

confidence: 99%